The Antileukemia Activity of ZSTK474 on U937 Cells.
10.19746/j.cnki.issn.1009-2137.2021.01.003
- Author:
Ting CHEN
1
;
Qian-Xiang ZHOU
1
;
Yu-Ling QIU
2
;
De-Xin KONG
3
Author Information
1. School of Pharmacy, Tianjin Medical University, Tianjin 300070, China.
2. School of Pharmacy, Tianjin Medical University, Tianjin 300070, China E-mail: qiuyuling@tmu.edu.cn.
3. School of Pharmacy, Tianjin Medical University, Tianjin 300070, China E-mail: kongdexin@tmu.edu.cn.
- Publication Type:Journal Article
- MeSH:
Apoptosis;
Cell Line, Tumor;
Cell Proliferation;
Glycogen Synthase Kinase 3 beta;
Humans;
Phosphatidylinositol 3-Kinases;
Proto-Oncogene Proteins c-akt;
Triazines;
U937 Cells
- From:
Journal of Experimental Hematology
2021;29(1):17-25
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the antileukemia activity of phosphatidylinositol-3 kinase (PI3K) inhibitor ZSTK474 on human leukemia cell line U937.
METHODS:MTT, soft agar assay, flow cytometric analysis and western blot were used to detect the effect of ZSTK474 on U937 cell proliferation, tumorigenicity, cell cycle, cell apoptosis and phosphorylation levels of the key factor of PI3K/AKT pathway. Chou-Talalay method was used to evaluate the combination of ZSTK474 with Cytarabine or Homoharringtonine.
RESULTS:PI3K inhibitor ZSTK474 could inhibit the proliferation and tumorigenicity of U937 cell, induce G
CONCLUSION:ZSTK474 can inhibit the pathway of PI3K/AKT, ZSTK474 alone or in combination with Homoharringtonine shows potential antileukemia activity on U937 cells.
